Beneficial Effect of Polydeoxyribonucleotide in the Treatment of Actinic Cheilitis: A Case Report

Actinic cheilitis (AC) is considered a potentially malignant disorder characterized by epithelial atrophy, chronic inflammation, and the progressive deterioration of the tissue architecture of the vermilion border of the lip. Currently, there is no effective minimally invasive treatment to reverse the progression of this pathology. The use of polydeoxyribonucleotide (PDRN) has demonstrated benefits across various dermatologic and wound-healing contexts due to its regenerative, angiogenic, and anti-inflammatory properties. This study aims to evaluate the healing effect of PDRN on AC lesions. This report describes the case of a 59-year-old woman with an ulcerated lesion persisting for more than two to three weeks on her lower lip, diagnosed as AC. Previous treatments with creams were unsuccessful and led to recurrence. A single subdermal infiltration of PDRN resulted in the restoration of epithelial integrity, reduced tissue fragility, and a significant improvement in oral function; that is, the patient can laugh and eat without pain after 21 days of treatment. These findings suggest that PDRN therapy is a minimally invasive option for tissue repair in AC, with potential preventive value against progression to squamous cell carcinoma. Further clinical studies are needed to confirm these results.